Trial · NCT07007195
Smart Olfaction App to Reduce Relapse
NCT07007195, Early phase 1, Recruiting, University of Houston
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Smart Olfaction App to Reduce Relapse. Trials, record NCT07007195. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07007195
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Smart Olfaction App to Reduce Relapse
- NCT number
- NCT07007195
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 132 participants, estimated
- Lead sponsor
- University of Houston
- Conditions
- Nicotine Dependence
- Interventions
Ad Libitum Use followed by Instructed Use of the Inspire Device, Instructed Use followed by Ad Libitum Use of the Inspire Device, Smart-T Smoking Cessation App with the Inspire Device Condition, Smart-T Smoking Cessation App Without the Inspire Device Condition, Nicotine replacement therapy (NRT), Inspire Device
- First posted
- 2025-06-05
- Last updated
- 2026-07-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | OSDS Use | Phase I: Post randomization to End of Study (14 days post-quit date) | Descriptive data regarding use times and frequency will be assessed. |
| Primary | Odor Assessment | Phase I: Post randomization to End of Study (14 days post-quit date) | Reports of odor assessment will be used to determine if sniffing specific odors reduce craving more than an odor blank. |
| Primary | Craving Reduction | Phase I: Post randomization to End of Study (14 days post-quit date). Phase II: Post randomization to End of Study (12 weeks post-quit date) | Participants will report craving levels multiple times per day via the app. Reduction in craving levels over time will be analyzed. |
| Primary | Device Acceptability | Phase I: End of Study (14 days post-quit date). Phase II: End of Study (12 weeks post-quit date) | Participant satisfaction ratings and qualitative feedback. Acceptability will be assessed through post-intervention surveys and qualitative interviews, focusing on perceived usefulness, ease of use, and overall satisfaction. |
| Primary | Smoking Abstinence | Phase II: Randomization to End of Study | Biochemically confirmed 7-day point prevalence abstinence 12 weeks following the scheduled quit day. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07007195
GET https://conductscience.org/api/trials/v1/NCT07007195/registered